A road map for the treatment of pediatric diffuse midline glioma.

Carl Koschmann,Wajd N Al-Holou,Marta M Alonso,Jamie Anastas,Pratiti Bandopadhayay,Tara Barron,Oren Becher,Rodrigo Cartaxo,Maria G Castro,Chan Chung, Madison Clausen,Derek Dang,Robert Doherty,Ryan Duchatel,Matthew Dun,Mariella Filbin,Andrea Franson,Stefanie Galban, Marc Garcia Moure,Hugh Garton,Pruthvi Gowda,Joana Graca Marques,Cynthia Hawkins,Allison Heath,Esther Hulleman,Sunjong Ji,Chris Jones,Lindsay Kilburn,Cassie Kline, Michael A Koldobskiy,Daniel Lim,Pedro R Lowenstein,Q Richard Lu, Joanna Lum,Stephen Mack,Suresh Magge,Bernard Marini,Donna Martin, Neena Marupudi,Dana Messinger,Rajen Mody,Meredith Morgan,Mateus Mota,Karin Muraszko,Sabine Mueller,Siva Kumar Natarajan,Javad Nazarian, Michael Niculcea, Nicholas Nuechterlein,Hideho Okada,Valerie Opipari,Manjunath P Pai,Sharmistha Pal,Erik Peterson,Timothy Phoenix,John R Prensner,Matthew Pun,G Praveen Raju,Zachary J Reitman,Adam Resnick, David Rogawski,Amanda Saratsis,Stefanie G Sbergio,Mark Souweidane, James M Stafford,Theophilos Tzaridis,Sujatha Venkataraman,Orazio Vittorio,Jack Wadden,Daniel Wahl, Robert J Wechsler-Reya,Viveka Nand Yadav,Xu Zhang,Qiang Zhang,Sriram Venneti

Cancer cell（2023）

引用 0|浏览16

暂无评分

摘要

Recent clinical trials for H3K27-altered diffuse midline gliomas (DMGs) have shown much promise. We present a consensus roadmap and identify three major barriers: (1) refinement of experimental models to include immune and brain-specific components; (2) collaboration among researchers, clinicians, and industry to integrate patient-derived data through sharing, transparency, and regulatory considerations; and (3) streamlining clinical efforts including biopsy, CNS-drug delivery, endpoint determination, and response monitoring. We highlight the importance of comprehensive collaboration to advance the understanding, diagnostics, and therapeutics for DMGs.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要